KR100339874B1 - 글루코오스 내성을 개선하기 위한 제약 조성물 - Google Patents

글루코오스 내성을 개선하기 위한 제약 조성물 Download PDF

Info

Publication number
KR100339874B1
KR100339874B1 KR1019960704203A KR19960704203A KR100339874B1 KR 100339874 B1 KR100339874 B1 KR 100339874B1 KR 1019960704203 A KR1019960704203 A KR 1019960704203A KR 19960704203 A KR19960704203 A KR 19960704203A KR 100339874 B1 KR100339874 B1 KR 100339874B1
Authority
KR
South Korea
Prior art keywords
glucose tolerance
compound
pharmaceutically acceptable
pharmaceutical compositions
dimethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1019960704203A
Other languages
English (en)
Korean (ko)
Inventor
레이몬 바르가스
Original Assignee
크놀 게엠베하
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22703362&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR100339874(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 크놀 게엠베하 filed Critical 크놀 게엠베하
Application granted granted Critical
Publication of KR100339874B1 publication Critical patent/KR100339874B1/ko
Assigned to 애보트 게엠베하 운트 콤파니 카게 reassignment 애보트 게엠베하 운트 콤파니 카게 권리의 전부이전등록 Assignors: 크놀 게엠베하
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Polyesters Or Polycarbonates (AREA)
  • Lubricants (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Materials For Medical Uses (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1019960704203A 1994-02-03 1995-02-03 글루코오스 내성을 개선하기 위한 제약 조성물 Expired - Fee Related KR100339874B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/190,924 US5459164A (en) 1994-02-03 1994-02-03 Medical treatment
US08/190,924 1994-02-03
PCT/US1995/001190 WO1995020949A1 (en) 1994-02-03 1995-02-03 Improving glucose tolerance

Publications (1)

Publication Number Publication Date
KR100339874B1 true KR100339874B1 (ko) 2002-11-22

Family

ID=22703362

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019960704203A Expired - Fee Related KR100339874B1 (ko) 1994-02-03 1995-02-03 글루코오스 내성을 개선하기 위한 제약 조성물

Country Status (17)

Country Link
US (2) US5459164A (https=)
EP (1) EP0814788B1 (https=)
JP (1) JPH10503166A (https=)
KR (1) KR100339874B1 (https=)
CN (1) CN1070698C (https=)
AT (1) ATE205390T1 (https=)
AU (1) AU694761B2 (https=)
CA (1) CA2182620C (https=)
DE (1) DE69522716T2 (https=)
DK (1) DK0814788T3 (https=)
ES (1) ES2166817T3 (https=)
IL (1) IL112515A (https=)
PH (1) PH31220A (https=)
PT (1) PT814788E (https=)
TW (1) TW314466B (https=)
WO (1) WO1995020949A1 (https=)
ZA (1) ZA95814B (https=)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9619757D0 (en) * 1996-09-21 1996-11-06 Knoll Ag Chemical process
GB9619961D0 (en) * 1996-09-25 1996-11-13 Knoll Ag Medical treatment
GB9619962D0 (en) * 1996-09-25 1996-11-13 Knoll Ag Medical treatment
GB9727131D0 (en) 1997-12-24 1998-02-25 Knoll Ag Therapeutic agents
US6476078B2 (en) * 1999-08-11 2002-11-05 Sepracor, Inc. Methods of using sibutramine metabolites in combination with a phosphodiesterase inhibitor to treat sexual dysfunction
US6339106B1 (en) 1999-08-11 2002-01-15 Sepracor, Inc. Methods and compositions for the treatment and prevention of sexual dysfunction
US6974838B2 (en) * 1998-08-24 2005-12-13 Sepracor Inc. Methods of treating or preventing pain using sibutramine metabolites
US6331571B1 (en) 1998-08-24 2001-12-18 Sepracor, Inc. Methods of treating and preventing attention deficit disorders
US6323242B1 (en) 1998-12-02 2001-11-27 Peter Sterling Mueller Treatment of disorders secondary to organic impairments
US6696495B2 (en) 1998-12-02 2004-02-24 Snowden Pharmaceuticals, Llc Treatment of disorders secondary to organic impairments
BG65170B1 (bg) * 1999-03-17 2007-05-31 Knoll Gmbh Използване на n-заместени производни на 1-[1-(4-хлорофенил)циклобутил]-3-метилбутиламин за производство на лекарство за лечение на разстройства при храненето
AU3757800A (en) * 1999-03-19 2000-10-09 Abbott Gmbh & Co. Kg Method of controlling weight gain associated with therapeutic drugs
WO2000056321A1 (en) 1999-03-19 2000-09-28 Knoll Pharmaceutical Company Treatment of hyperactivity disorders
WO2000056309A1 (en) * 1999-03-19 2000-09-28 Knoll Pharmaceutical Company Method of treating sexual dysfunction
AU3894500A (en) * 1999-03-19 2000-10-09 Knoll Pharmaceutical Company Prevention of cardiovascular disease
US6552087B1 (en) 1999-03-19 2003-04-22 Abbott Gmbh & Co. Kg Therapeutic agent comprising (+)-sibutramine
JP2002539252A (ja) * 1999-03-19 2002-11-19 クノール・ゲー・エム・ベー・ハー 胆石の治療
US6803387B1 (en) * 1999-03-19 2004-10-12 Abbott Gmbh & Co. Kg Treatment of neuropathic pain or fibromyalgia
US6403650B1 (en) * 1999-03-19 2002-06-11 Knoll Pharmaceutical Company Treatment of pulmonary hypertension
EP1169029B1 (en) * 1999-03-19 2005-05-04 Abbott GmbH & Co. KG Use of sibutramine or its derivative for the treatment of sleep disorders
WO2000056319A1 (en) 1999-03-19 2000-09-28 Knoll Pharmaceutical Company Treatment of orthostatic hypotension
IL145238A0 (en) * 1999-03-19 2002-06-30 Knoll Gmbh Treatment of osteoarthritis
WO2000056311A1 (en) * 1999-03-19 2000-09-28 Knoll Pharmaceutical Company Control of metabolism
AU3896900A (en) * 1999-03-19 2000-10-09 Knoll Pharmaceutical Company Treatment of pain
WO2000056310A1 (en) * 1999-03-19 2000-09-28 Knoll Pharmaceutical Company Treatment of chronic fatigue syndrome
US6372797B1 (en) 1999-03-19 2002-04-16 Knoll Pharmaceutical Company Treatment of menstrual function
MXPA01009470A (es) * 1999-03-19 2004-03-19 Knoll Gmbh Tratamiento de ciertos canceres asociados con el aumento de peso.
GB9914744D0 (en) * 1999-06-24 1999-08-25 Knoll Ag Therapeutic agents
US6399826B1 (en) 1999-08-11 2002-06-04 Sepracor Inc. Salts of sibutramine metabolites, methods of making sibutramine metabolites and intermediates useful in the same, and methods of treating pain
GB9926251D0 (en) * 1999-11-06 2000-01-12 Knoll Ag Pharmaceutical formulation
US6232347B1 (en) 2000-03-17 2001-05-15 Knoll Pharmaceutical Company Treatment of osteoarthritis
US6610887B2 (en) 2001-04-13 2003-08-26 Sepracor Inc. Methods of preparing didesmethylsibutramine and other sibutramine derivatives
US6602911B2 (en) 2001-11-05 2003-08-05 Cypress Bioscience, Inc. Methods of treating fibromyalgia
US20040034101A1 (en) * 2001-11-05 2004-02-19 Cypress Bioscience, Inc. Treatment and prevention of depression secondary to pain (DSP)
JP4278652B2 (ja) * 2002-10-05 2009-06-17 ハンミ ファーム． シーオー．， エルティーディー． 結晶性シブトラミンメタンスルホン酸塩半水和物を含む医薬組成物
US20050131074A1 (en) * 2003-08-04 2005-06-16 Beckman Kristen M. Methods for treating metabolic syndrome
WO2006073292A1 (en) 2005-01-06 2006-07-13 Cj Corporation Inorganic acid salts of sibutramine
KR100627687B1 (ko) * 2005-04-20 2006-09-25 주식회사 씨티씨바이오 시부트라민 유리염기 함유 조성물 및 이의 제조방법
US7994220B2 (en) * 2005-09-28 2011-08-09 Cypress Bioscience, Inc. Milnacipran for the long-term treatment of fibromyalgia syndrome
KR20080046601A (ko) * 2006-11-22 2008-05-27 에스케이케미칼주식회사 보관안정성이 우수한 시부트라민 함유 포접복합체

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE52768B1 (en) * 1981-04-06 1988-02-17 Boots Co Ltd 1-arylcyclobutylalkylamine compounds useful as therapeutic agents
GB8531071D0 (en) * 1985-12-17 1986-01-29 Boots Co Plc Therapeutic compound
GB8704777D0 (en) * 1987-02-28 1987-04-01 Boots Co Plc Medical treatment
DE3883606T2 (de) * 1987-05-04 1994-01-20 Lilly Co Eli Verwendung von Fluoxetin zur Behandlung des Diabetes.
JP2675573B2 (ja) * 1988-03-31 1997-11-12 科研製薬株式会社 脳機能改善剤
IE61928B1 (en) * 1988-11-29 1994-11-30 Boots Co Plc Treatment of obesity

Also Published As

Publication number Publication date
JPH10503166A (ja) 1998-03-24
ZA95814B (en) 1995-08-03
AU1736295A (en) 1995-08-21
IL112515A (en) 2000-07-26
AU694761B2 (en) 1998-07-30
CA2182620C (en) 2007-01-16
PH31220A (en) 1998-05-05
CN1144479A (zh) 1997-03-05
EP0814788A4 (en) 1999-05-06
IL112515A0 (en) 1995-12-08
CN1070698C (zh) 2001-09-12
TW314466B (https=) 1997-09-01
US5459164A (en) 1995-10-17
WO1995020949A1 (en) 1995-08-10
EP0814788B1 (en) 2001-09-12
ATE205390T1 (de) 2001-09-15
DE69522716D1 (de) 2001-10-18
PT814788E (pt) 2002-03-28
US5942549A (en) 1999-08-24
CA2182620A1 (en) 1995-08-10
DK0814788T3 (da) 2001-11-19
DE69522716T2 (de) 2002-05-29
ES2166817T3 (es) 2002-05-01
EP0814788A1 (en) 1998-01-07

Similar Documents

Publication Publication Date Title
KR100339874B1 (ko) 글루코오스 내성을 개선하기 위한 제약 조성물
AU773188C (en) Method of treating eating disorders
CN1237905A (zh) 应用Sibutramine类似物预防糖尿病的发展
EP1007023B1 (en) 1-[1-(4-chlorophenyl)cyclobutyl]-3-methylbutyl amine derivatives for lowering the uric level in humans
WO2000056315A1 (en) Treatment of pain
WO2000056318A1 (en) Treatment of neuropathic pain or fibromyalgia
WO2000056310A1 (en) Treatment of chronic fatigue syndrome
WO2000056320A1 (en) Treatment of menstrual function
WO2000056311A1 (en) Control of metabolism
JP2002539254A (ja) 血小板粘着性を低下させるための治療
WO2000056148A1 (en) Treatment of pharmacology of drug misuse and other addictive disorders
CN1352552A (zh) 关于骨关节炎的治疗
US20030013735A1 (en) Weight loss after pregnancy
JP2002539249A (ja) 裂孔ヘルニアの治療
MXPA01007388A (es) Metodo para ayudar a dejar de fumar.
MXPA99002598A (en) Use of sibutramine analogues to prevent the development of diabetes
CA2367268A1 (en) Weight loss after pregnancy
BG65170B1 (bg) Използване на n-заместени производни на 1-[1-(4-хлорофенил)циклобутил]-3-метилбутиламин за производство на лекарство за лечение на разстройства при храненето

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

N231 Notification of change of applicant
PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

R17-X000 Change to representative recorded

St.27 status event code: A-5-5-R10-R17-oth-X000

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R11-asn-PN2301

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R14-asn-PN2301

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 8

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 9

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 10

FPAY Annual fee payment

Payment date: 20120427

Year of fee payment: 11

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 11

FPAY Annual fee payment

Payment date: 20130429

Year of fee payment: 12

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 12

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20140526

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20140526